CMS finalises international benchmark model for Medicare Part B drugs

By ··1 min read

CMS finalised the GLOBE drug-payment model, with initial reporting in January 2027 and its performance period beginning April 2027. The rule is a payment-policy measure, not an enforcement finding against manufacturers.

The Centers for Medicare & Medicaid Services announced its final Global Benchmark for Efficient Drug Pricing model on September 30, 2026. The GLOBE rule, CMS-5545-F, was published in the Federal Register on October 2 as document 2026-20281. It tests an alternative calculation for rebates on selected Medicare Part B drugs using international prices.

CMS relied on section 1115A of the Social Security Act and codified the model at 42 C.F.R. part 513. It covers certain drugs generally administered by clinicians and applies in selected geographic areas representing approximately one-quarter of beneficiaries with Original Medicare as their primary coverage.

The final design excludes specified categories, including orphan-only drugs, plasma-derived products and certain cell and gene therapies. CMS also said biosimilars and their reference biological products would be excluded once a biosimilar enters the U.S. market. These exclusions affect scope; they are not findings about manufacturers' compliance.

The final rule discusses potential waivers for manufacturers participating in other CMS initiatives. Its savings estimates assume that manufacturers with signed GENEROUS participation agreements will not participate in GLOBE. The rule does not support treating every major drugmaker as facing an identical new payment obligation.

The model begins with an initial reporting period on January 1, 2027. The five-year performance period runs from April 1, 2027, through March 31, 2032, followed by reconciliation through March 31, 2034. The announcement imposes no company-specific fine and adds no enforcement action to the Redflag Index.

Cite this report

The Precedent. "CMS finalises international benchmark model for Medicare Part B drugs." October 3, 2026. https://theprecedent.org/article/cms-finalises-international-benchmark-model-for-medicare-part-b-drugs